13 results about "Biopterin" patented technology

The invention relates to the technical field of aquaculture, in particular to a leiocassis longirostris intestinal health functional additive based on spermaceti soxhlet metabolite. The Leiocassis longirostris intestinal health functional additive comprises the following functional components: chondroitin sulfate, N-acetyl-D-galactosamine, 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4'- The composition is prepared from the following raw materials: 4, 6-dihydroxyflavone, polydatin, ascorbic acid, glucoside, arabinogalactan, 3-O-beta-D-galactopyranosyl-L-arabinose, tyramine, 4A-hydroxytetrahydrobiopterin, hyaluronic acid and 3-mercapto-2-butanol. According to the technical scheme, the technical problem that an existing probiotic viable bacterium preparation is difficult to meet the intestinal health management requirement in intensive culture of the leiocassis longirostris can be solved. Compared with the prior art, the scheme is more efficient, stable and safe, healthy development of the Leiocassis longirostris breeding industry can be effectively promoted, and the method has ideal application and popularization prospects.

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.

The present invention belongs to the field of biological detection technology, and discloses a method for rapid detection of neopterin, biopterin, pterin and 7-biopterin in urine. Specifically disclosed is the application of perfluorobutyric acid in improving the detection effect of pterin spectrum in urine based on liquid chromatography. The present invention uses perfluorobutyric acid for the determination of pterin spectrum in urine. As an ion pair reagent of hydrophobic anions, it can significantly enhance the separation effect of each pterin spectrum (such as biopterin, neopterin, pterin and 7-biopterin), and can significantly improve the detection accuracy of pterin spectrum.

The invention relates to a method for detecting related substances in sapropterin hydrochloride tablets. The related substances are selected from biological pterin, pterin, neopterin, pteridine and S-isomer. High performance liquid chromatography is adopted for detection, and a filling material of a stationary phase of a chromatographic column is octadecylsilane chemically bonded silica; a ghost peak trapping small column is arranged between the position behind the converging outlet of the pump and the sample injector; the mobile phase A is a phosphate buffer solution with the concentration of 10-30 mmol / L, and the pH value of the mobile phase A is 2.75-2.80; a mobile phase B is methanol; dissolving a to-be-detected sample with a diluent, and fixing the volume to form a sample injection solution; the diluent is a phosphate buffer solution containing ascorbic acid, the concentration of the phosphate buffer solution is 10-30 mmol / L, the pH value is 2.0-2.5, and the concentration of the ascorbic acid is 1-2 g / L.

Disclosed is a method of method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solution of a solid pharmaceutical composition containing a compound of formula (I) and / or formula (II), wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, witha compound having formula (I) being:and a compound having the formula (II) being:

Disclosed is a method of preparing a solution adapted for administration by infusion, comprisinga) a compound having the formula (I):and / or a compound having the formula (II):andb) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH2PO4·2H2O and Na2HPO4·2H2O, and wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the composition is chosen such that the molar ratio of both NaH2PO4·H2O and Na2HPO4·2H2O to compound (I) or compound (II) ranges from 0.02 to 0.5 and optionally NaCl. Also disclosed is a method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a reconstituted solution as disclosed.

The invention discloses an application of tetrahydrobiopterin in enhancing functions of dendritic cells and relieving related diseases, and finds that tetrahydrobiopterin can promote maturation of the dendritic cells, improve antigen processing and presenting capabilities of the dendritic cells and / or enhance T cell activation capability mediated by the dendritic cells for the first time. The tetrahydrobiopterin can promote synergistic activation of vaccine-induced humoral immunity and cellular immunity by enhancing the dendritic cell function, and the invention provides a new thought and strategy for vaccine research and development, and has important scientific significance and clinical application value.

Methods of reducing viability of a parasite in a subject involve administering an effective amount of an inhibitor of guanosine-5′-triphosphate cyclohydrolase I (GCH) to the subject. Methods of identifying an agent that reduces viability of an apicomplexan parasite involve culturing an apicomplexan parasite in a cell culture; adding an agent to the cell culture; and detecting a concentration of one or more of 7,8-dihydroncopterin triphosphate, 6-pynivoyl-tetrahydropterin, tetrahydrobiopterin, tetrahydrofolate, folate, dihydrofolate, or dihydrobiopterin in the cell culture after a period of time.

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.

The invention belongs to the field of biological medicine, and relates to application of a tetrahydrobiopterin pathway as a target spot in resisting QDPR deletion type tumors. Particularly relates to application of a tetrahydrobiopterin bioactive agonist in preparation of an immunotherapy sensitizer or a drug resistance reversal agent for QDPR low-expression or deletion tumors. It is found for the first time that the biological activity of tetrahydrobiopterin is improved, the sensitivity of QDPR low-expression or deletion tumors to immunotherapy can be greatly improved, and the treatment effectiveness of an immune checkpoint blocking agent serving as an anti-tumor drug is improved. The invention has an extremely important meaning for treating tumors resisted by immunotherapy.

The present invention relates to the use of Inopterin and its metabolites to treat radiation exposure. The present invention provides methods for treating radiation exposure in a subject by administering Inopterin, Tetrahydrobiopterin, or Dihydrobiopterin.

The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.